Ownership history in CITADEL ADVISORS LLC Β· 33 quarters on record
This page tracks every 13F SEC filing in which CITADEL ADVISORS LLC reported a position in CARDIOL THERAPEUTICS INC (CRDL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π CITADEL ADVISORS LLC outperformed the S&P 500 by +18.4% annually on this CRDL position. Timing score: 50% (16/32 decisions correct). Average cost basis: $1.30. Maximum drawdown during holding period: β73.5%.
π₯ Exceptional β beat the S&P 500 by 18.4% per year on this position.
20 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
16 of 32 add/trim decisions correct
Best entry: $0.49 (2023 Q1) Β· Worst: $2.02 (2024 Q2)
πͺ Held through 2 major drawdowns (>20%).
16 adds Β· 17 trims. Bought during 3 of 11 down-price quarters. π Predominantly trimming β distribution phase.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size